VIDEO: Orismilast reaches primary endpoint in psoriasis treatment phase 2b study
Click Here to Manage Email Alerts
In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on a study of orismilast, a novel phosphodiesterase-4 inhibitor, in the treatment of psoriasis.
In the phase 2b study, individuals were administered 20 mg, 30 mg, or 40 mg twice-daily orismilast or placebo. The two higher doses of the study drug showed that 49% and 45% of patients, respectively, reached the primary endpoint of PASI 75 by week 16, according to Wu, a voluntary associate professor in the department of dermatology at University of Miami Miller School of Medicine.
Also, 38% to 48% of orismilast-treated participants reported nausea and diarrhea compared with 4% of the placebo group.
Reference:
- French L. Efficacy and safety of orismilast in patients with moderate to severe psoriasis: Results from the phase IIb IASOS trial. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.